CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x March 31, 2013

[FORM 10-Q (Mark One) x March 31, 2013 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Nevada 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:May 14, 2013 President and Chief Executive Officer (principal financial officer and principal accounting officer) cphi10qex321033113.htm]

By | 2016-02-07T21:40:28+00:00 May 14th, 2013|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-K: (Original Filing)

[FORM 10-K x For the fiscal year ended December 31, 2012 or ¨ For the transition period from _________ to _____________ China Pharma Holdings, Inc. Nevada 73-1564807 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730 Title of each class Name of each] [December 24, 2012 Dear Ms. Heung Mei Tsui On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc as a director. The compensation is $16,000 per year. I look forward to working with you. Your starting date will be the December 24, 2012, and] [Re: Service about being independent director, Chairman of the Nominating and Compensation Committee, and member of the Audit Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Yingwen Zhang, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, member of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Baowen Dong, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, chairman of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Gene Michael Bennett, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an] [Loans Extension Agreement With respect to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the Company), the principal and accumulated interest totaled USD $1,354,567 and $17,122 respectively as of December 31, 2012. Because the Company temporarily did not have enough balance in its oversea account to repay the loans, Ms. Tsui and the Company unanimously agreed] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 13, 2013 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries appearing in this Annual Report on Form 10-K of China Pharma] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 14, 2013 President and Chief Executive Officer EX-32.1 10 cphi10kex321123112.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 14, 2013 (principal financial officer and principal accounting officer) EX-32.2 11 cphi10kex322123112.htm]

By | 2016-03-03T16:59:45+00:00 March 14th, 2013|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-K: FORM 10-K x For the fiscal year ended

[FORM 10-K x For the fiscal year ended December 31, 2012 or ¨ For the transition period from _________ to _____________ China Pharma Holdings, Inc. Nevada 73-1564807 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730 Title of each class Name of each] [December 24, 2012 Dear Ms. Heung Mei Tsui On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc as a director. The compensation is $16,000 per year. I look forward to working with you. Your starting date will be the December 24, 2012, and] [Re: Service about being independent director, Chairman of the Nominating and Compensation Committee, and member of the Audit Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Yingwen Zhang, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, member of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Baowen Dong, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, chairman of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Gene Michael Bennett, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an] [Loans Extension Agreement With respect to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the Company), the principal and accumulated interest totaled USD $1,354,567 and $17,122 respectively as of December 31, 2012. Because the Company temporarily did not have enough balance in its oversea account to repay the loans, Ms. Tsui and the Company unanimously agreed] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 13, 2013 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries appearing in this Annual Report on Form 10-K of China Pharma] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 14, 2013 President and Chief Executive Officer EX-32.1 10 cphi10kex321123112.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 14, 2013 (principal financial officer and principal accounting officer) EX-32.2 11 cphi10kex322123112.htm]

By | 2016-03-03T17:01:54+00:00 March 14th, 2013|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-K: (Original Filing)

[FORM 10-K x For the fiscal year ended December 31, 2012 or For the transition period from _________ to _____________ China Pharmas, Nevada 73-1564807 (State or other jurisdiction oforporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730] [December 24, 2012 Dear Ms. Heung Mei Tsui On behalf of the Board of Directors and thempany, I am pleased to welcome you to join the Board of the China Pharmas, a director. Thempensation is $16,000 per year. I look forward to working with you. Your startingte will be the December 24, 2012, and the] [Re: Serviceout being independent director, Chairman of the Nominating andmpensationmmittee, and member of the Auditmmittee of China Pharmas, December 24, 2012 Dear Mr. Yingwen Zhang, On behalf of the Board of Directors and thempany, I am pleased to welcome you to join the Board of the China Pharmas, an independent director, Chairman of the Nominating] [Re: Serviceout being independent director, member of the Auditmmittee, and member of the Nominating andmpensationmmittee of China Pharmas, December 24, 2012 Dear Mr. Baowen Dong, On behalf of the Board of Directors and thempany, I am pleased to welcome you to join the Board of the China Pharmas, an independent director, member of the Auditmmittee,] [Re: Serviceout being independent director, chairman of the Auditmmittee, and member of the Nominating andmpensationmmittee of China Pharmas, December 24, 2012 Dear Mr. Gene Michael Bennett, On behalf of the Board of Directors and thempany, I am pleased to welcome you to join the Board of the China Pharmas, an independent director, chairman of the] [Loans Extensionreement With respect to the loans from Ms. Heung Mei Tsui to China Pharmas, (thempany), the principal and accumulated interest totaled USD $1,354,567 and $17,122 respectively of December 31, 2012. Because thempany temporarily did not have enough balance in its oversea account to repay the loans, Ms. Tsui and thempany unanimouslyreed to extend the] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Wensent to theorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our reportted March 13, 2013 relating to thensolidated financial statements of China Pharmas, and subsidiaries appearing in this Annual Report on Form 10-K of China Pharmas, for] [CERTIFICATION OF OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:March 14, 2013 President and Chief Executive Officer cphi10kex321123112.htm 10 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:March 14, 2013 (principal financial officer and principal accounting officer) cphi10kex322123112.htm 11 EX-32.2]

By | 2016-02-07T21:42:17+00:00 March 14th, 2013|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] SC 13G: (Original Filing)

[for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose (Act) or otherwise subject to]

By | 2016-03-03T17:03:32+00:00 February 14th, 2013|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] SC 13G: for a reporting persons initial filing on this

[for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose (Act) or otherwise subject to]

By | 2016-03-03T17:05:40+00:00 February 14th, 2013|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] SC 13G: (Original Filing)

[1. Names of Reporting Persons. Popeset Management, I.R.S. Identification Nos. ofove persons 62-1871308 2. Check the Appropriate Box if a Member of a (a) (b) 3. SEC Use Only 4. Citizenship or Place of Organization Tennessee Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power 2,224,831* 6. Shared Voting Power]

By | 2016-02-07T21:43:47+00:00 February 14th, 2013|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] SC 13G: 1. Names of Reporting Persons. Popeset Management, I.R.S.

[1. Names of Reporting Persons. Popeset Management, I.R.S. Identification Nos. ofove persons 62-1871308 2. Check the Appropriate Box if a Member of a (a) (b) 3. SEC Use Only 4. Citizenship or Place of Organization Tennessee Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power 2,224,831* 6. Shared Voting Power]

By | 2016-02-07T21:44:41+00:00 February 14th, 2013|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] SC 13G/A: (Original Filing)

[CUSIP No. 16941T104 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OFOVE PERSONS (ENTITIES ONLY) Peter Siris 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A (SEE INSTRUCTIONS) (a)[_] (b)[X] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH]

By | 2016-02-07T21:46:00+00:00 February 12th, 2013|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar